Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial

HIGHLIGHTS: What are the main findings? Favipiravir, an RNA-dependent RNA polymerase inhibitor, shows no benefit in preventing the hospitalization of mild to moderate COVID-19 patients. What is the implication of the main finding? Our results may inform decisions on the exclusion of Favipiravir from...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaezi, Atefeh, Salmasi, Mehrzad, Soltaninejad, Forogh, Salahi, Mehrdad, Javanmard, Shaghayegh Haghjooy, Amra, Babak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951951/
https://www.ncbi.nlm.nih.gov/pubmed/36825938
http://dx.doi.org/10.3390/arm91010004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951951/
https://www.ncbi.nlm.nih.gov/pubmed/36825938
http://dx.doi.org/10.3390/arm91010004

Ejemplares similares